Sorafenib for Residue Disease After Resection With Curative Intent
NCT01751763
·
clinicaltrials.gov ↗
COMPLETED
Status
106
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Hepatocellular
Interventions
DRUG:
Sorafenib (Nexavar, BAY43-9006)
Sponsor
Bayer